Toronto Stock Exchange (12,380.41 down 119.34 points):
Baja Mining Corp. (TSX:BAJ). Miner. Up four cents, or 38.10 per cent, at 14.5 cents on 7,111,997 shares.
Bombardier Inc. (TSX:BBD.B). Transportation equipment. Down eight cents, or 2.13 per cent, at $3.68 on 5,566,161 shares. The plane and train maker’s plant northeast of Quebec City began its first strike Thursday in more than 30 years over concerns about sub-contracting, pensions and wages. The plant is building the sidewalls and roofs for an order from Toronto for 420 subway cars and interior finishings for 706 Chicago transit cars.
Talisman Energy Inc. (TSX:TLM). Oil and gas. Down 21 cents or 1.86 per cent, at $11.10 on 5,559,741 shares. The energy sector had one of the biggest declines, dropping 1.47 per cent to 258.46 points. The December crude contract fell US$2.23 to $84.86 per barrel on the New York Mercantile Exchange.
Kinross Gold Corp. (TSX:K). Miner. Down 55 cents, or 5.56 per cent, at $9.34 on 5,419,317 shares. The gold sector had the largest drop, falling 4.41 per cent to 324.56 points.
New Gold Inc. (TSX:NGD). Miner. Down $1.03, or 8.74 per cent, at $10.75 on 5,388,647 shares.
Yamana Gold Inc. (TSX:YRI). Miner. Down $1.02, or 5.09 per cent, at $19 on 4,879,378 shares.
TSX Venture Exchange (1,310.03 down 11.26 points):
Porto Energy Corp. (TSXV:PEC). Oil and gas explorer. Down 4.5 cents, or 45 per cent, at 5.5 cents on 11,122,416 shares.
Prodigy Gold Inc. (TSX:PDG). Miner developer. Down two cents, or 1.87 per cent, at $1.05 on 3,471,402 shares.
Companies reporting major news:
Thomson Reuters (TSX:TRI). Data and information. Down 37 cents, or 1.30 per cent, at $28.06 on 1,090,306 shares. The specialized news provider earned a profit of US$462 million or 56 cents per share compared with $369 million or 44 cents in the same period last year. Revenue totalled $3.22 billion, down from $3.45 billion.
Valeant Pharmaceuticals International Inc. (TSX:VRX). Drug maker. Down 33 cents, or 0.58 per cent, at $56.20 on 645,923 shares. Canada's largest publicly traded drug maker says acquisition and other costs drove its third-quarter profits 81 per cent lower despite a 50 per cent rise on revenues.